A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 04 Jul 2015 Trial design presented at the 17th World Congress on Gastrointestinal Cancer.
- 31 May 2014 Planned number of patients changed from 52 to 42 according to the trial protocol presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 30 Sep 2013 New trial record